Animal models for Ebola and Marburg virus infections
Top Cited Papers
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 4, 267
- https://doi.org/10.3389/fmicb.2013.00267
Abstract
Ebola and Marburg hemorrhagic fevers (EHF and MHF) are caused by the Filoviridae family, Ebolavirus and Marburgvirus (ebolavirus and marburgvirus), respectively. These severe diseases have high mortality rates in humans. Although EHF and MHF are endemic to sub-Saharan Africa. A novel filovirus, Lloviu virus, which is genetically distinct from ebolavirus and marburgvirus, was recently discovered in Spain where filoviral hemorrhagic fever had never been reported. The virulence of this virus has not been determined. Ebolavirus and marburgvirus are classified as biosafety level-4 (BSL-4) pathogens and Category A agents, for which the US government requires preparedness in case of bioterrorism. Therefore, preventive measures against these viral hemorrhagic fevers should be prepared, not only in disease-endemic regions, but also in disease-free countries. Diagnostics, vaccines, and therapeutics need to be developed, and therefore the establishment of animal models for EHF and MHF is invaluable. Several animal models have been developed for EHF and MHF using nonhuman primates (NHPs) and rodents, which are crucial to understand pathophysiology and to develop diagnostics, vaccines, and therapeutics. Rhesus and cynomolgus macaques are representative models of filovirus infection as they exhibit remarkably similar symptoms to those observed in humans. However, the NHP models have practical and ethical problems that limit their experimental use. Furthermore, there are no inbred and genetically manipulated strains of NHP. Rodent models such as mouse, guinea pig, and hamster, have also been developed. However, these rodent models require adaptation of the virus to produce lethal disease and do not mirror all symptoms of human filovirus infection. This review article provides an outline of the clinical features of EHF and MHF in animals, including humans, and discusses how the animal models have been developed to study pathophysiology, vaccines, and therapeutics.Keywords
This publication has 100 references indexed in Scilit:
- Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus InfectionAntimicrobial Agents and Chemotherapy, 2009
- Replication-Deficient Ebolavirus as a Vaccine CandidateJournal of Virology, 2009
- Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challengeVirology, 2008
- Protection against lethal challenge by Ebola virus-like particles produced in insect cellsVirology, 2008
- Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman PrimatesJournal of Virology, 2008
- Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsClinical and Vaccine Immunology, 2008
- Ebola Virus VP24 Proteins Inhibit the Interaction of NPI-1 Subfamily Karyopherin α Proteins with Activated STAT1Journal of Virology, 2007
- Successful Topical Respiratory Tract Immunization of Primates against Ebola VirusJournal of Virology, 2007
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical TrialClinical and Vaccine Immunology, 2006
- Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant VaccineJournal of Virology, 2006